RU96121563A - USE OF BISPHOSPHONATES FOR INHIBITION OF BONE RESORPTION ARISING FROM IMPLANTATION OF ORTHOPEDIC PROSTHESES - Google Patents

USE OF BISPHOSPHONATES FOR INHIBITION OF BONE RESORPTION ARISING FROM IMPLANTATION OF ORTHOPEDIC PROSTHESES

Info

Publication number
RU96121563A
RU96121563A RU96121563/14A RU96121563A RU96121563A RU 96121563 A RU96121563 A RU 96121563A RU 96121563/14 A RU96121563/14 A RU 96121563/14A RU 96121563 A RU96121563 A RU 96121563A RU 96121563 A RU96121563 A RU 96121563A
Authority
RU
Russia
Prior art keywords
bone resorption
inhibitor
bisphosphonates
arising
implantation
Prior art date
Application number
RU96121563/14A
Other languages
Russian (ru)
Other versions
RU2161032C2 (en
Inventor
Дж.Эйтс Эшли
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/230,670 external-priority patent/US5646134A/en
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of RU96121563A publication Critical patent/RU96121563A/en
Application granted granted Critical
Publication of RU2161032C2 publication Critical patent/RU2161032C2/en

Links

Claims (8)

1. Способ лечения и/или предотвращения резорбции околопротезной костной ткани у субъекта, имеющего ортопедические имплантированные устройства, включающий введение указанному субъекту фармацевтически эффективного количества бисфосфонатного ингибитора резорбции кости.1. A method of treating and / or preventing resorption of peri-prosthetic bone tissue in a subject having orthopedic implanted devices, comprising administering to said subject a pharmaceutically effective amount of a bisphosphonate bone resorption inhibitor. 2. Способ по п.1, где субъектом является человек. 2. The method according to claim 1, where the subject is a person. 3. Способ по п.1, где лечение является профилактическим лечением. 3. The method according to claim 1, where the treatment is a preventive treatment. 4. Способ по п.1, где упомянутый ингибитор резорбции кости вводится в пероральной дозированной форме. 4. The method of claim 1, wherein said bone resorption inhibitor is administered in an oral dosage form. 5. Способ по п.1, где упомянутый ингибитор резорбции кости вводится парентерально. 5. The method of claim 1, wherein said bone resorption inhibitor is administered parenterally. 6. Способ по п.5, где упомянутый ингибитор резорбции кости вводится парентерально в участок околопротезной костной ткани. 6. The method according to claim 5, where the aforementioned inhibitor of bone resorption is introduced parenterally into the area of the prosthetic bone tissue. 7. Способ по п.1, где упомянутый бисфосфонатный ингибитор резорбции кости выбирается из группы, состоящей из алендроната, клодроната, тилюдроната, YM175, BM21.0995, этидроната, пиридроната, памидроната или их смеси. 7. The method according to claim 1, where the aforementioned bisphosphonate inhibitor of bone resorption is selected from the group consisting of alendronate, clodronate, tiludronate, YM175, BM21.0995, ethidronate, pyridronate, pamidronate or a mixture thereof. 8. Способ по п. 7, где упомянутый ингибитор резорбции кости является алендронатом. 8. The method of claim 7, wherein said bone resorption inhibitor is alendronate.
RU96121563/14A 1994-04-21 1995-04-17 Biphosphonate application for inhibiting bone resorption arising as a result of orthopedic prosthesis implantation RU2161032C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US230,670 1994-04-21
US08/230,670 US5646134A (en) 1994-04-21 1994-04-21 Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Publications (2)

Publication Number Publication Date
RU96121563A true RU96121563A (en) 1999-01-10
RU2161032C2 RU2161032C2 (en) 2000-12-27

Family

ID=22866129

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96121563/14A RU2161032C2 (en) 1994-04-21 1995-04-17 Biphosphonate application for inhibiting bone resorption arising as a result of orthopedic prosthesis implantation

Country Status (29)

Country Link
US (3) US5646134A (en)
EP (2) EP0756483B1 (en)
JP (1) JPH09512268A (en)
CN (1) CN1078073C (en)
AT (1) ATE236641T1 (en)
AU (1) AU2374895A (en)
BG (1) BG63102B1 (en)
CA (1) CA2188030C (en)
CO (1) CO4370025A1 (en)
CZ (1) CZ305596A3 (en)
DE (1) DE69530293T2 (en)
DK (1) DK0756483T3 (en)
DZ (1) DZ1873A1 (en)
ES (1) ES2194050T3 (en)
FI (1) FI964213A (en)
HR (1) HRP950239A2 (en)
HU (1) HUT74911A (en)
IL (1) IL113361A (en)
MY (1) MY114265A (en)
NO (1) NO312124B1 (en)
NZ (1) NZ284295A (en)
PL (1) PL318552A1 (en)
PT (1) PT756483E (en)
RU (1) RU2161032C2 (en)
SK (1) SK133396A3 (en)
TW (1) TW406021B (en)
WO (1) WO1995028936A1 (en)
YU (1) YU25295A (en)
ZA (1) ZA953185B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
CA2245793A1 (en) * 1996-02-14 1997-08-21 Itzhak Binderman Topical bisphosphonates for prevention of bone resorption
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
DE122007000063I1 (en) * 1997-07-22 2007-12-20 Merck & Co Inc Alendronate for the treatment of osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
PT1135140E (en) * 1998-12-04 2005-10-31 Roche Diagnostics Gmbh UTILIZATION OF IBANDRONATO FOR THE PROMOTION OF ENDOPROTESES OSSEA INTEGRATION
JP3219402B2 (en) 1998-12-25 2001-10-15 山之内製薬株式会社 Pharmaceutical composition for treating bone lesions in multiple myeloma
EP1210138A4 (en) * 1999-04-22 2003-05-07 Hydro Med Sciences Inc Controlled delivery of bisphosphonates
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
CH694935A5 (en) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte implants.
WO2002040073A1 (en) * 2000-11-20 2002-05-23 Université De Genève Endosseous implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US7425549B2 (en) * 2001-02-06 2008-09-16 The Royal Alexandra Hospital For Children Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
KR20020080018A (en) * 2001-04-10 2002-10-23 한국화학연구원 A controlled/sustained implant delivery containing bisphosphonate
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
CN100479823C (en) * 2001-12-21 2009-04-22 宝洁公司 The use of diphosphonate in producing medicine case and the case for increasing bone substance
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
KR20050010778A (en) * 2002-05-03 2005-01-28 밀레늄 바이올로직스 인코포레이티드 Connective tissue stimulating peptides
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US7674454B2 (en) * 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
KR100564628B1 (en) * 2004-06-16 2006-03-28 삼성전자주식회사 Split gate type flash mwmory device and method of manufacturing the same
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
FR2904784B1 (en) * 2006-08-10 2010-09-03 Surfactis Technologies PROCESS FOR RECOVERING METALLIC AND MINERAL SURFACES BY SELF-ASSEMBLED MONOMOUCHES OF BISPHOSPHONIC COMPOUNDS AND USES THEREOF
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
HUE025737T2 (en) 2009-09-01 2016-05-30 Univ Duke Bisphosphonate compositions and methods for treating heart failure
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
TR201903835T4 (en) 2010-12-06 2019-04-22 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with fast dissolution properties.
US8858979B1 (en) 2011-01-28 2014-10-14 Clemson University Service induced byproducts for localized drug delivery in orthopaedic implants
BR112013030298A2 (en) * 2011-05-27 2017-12-12 Ablynx Nv inhibition of bone resorption with rankl binding peptides
CN104010647A (en) 2011-11-16 2014-08-27 杜克大学 Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2653627C1 (en) * 2016-11-09 2018-05-11 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Method for modeling aseptic aminobisphosphonate osteonecrosis of lower jaws in laboratory white rats
US12029640B2 (en) 2017-12-07 2024-07-09 Paul V. Fenton, Jr. Method and injection system for bone tissue implant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
CN1046853C (en) * 1988-01-20 1999-12-01 山之内制药株式会社 (Cycloalkyl amine) methylene di (phosphonic acid) and drug taking this compound as active component
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
ATE195317T1 (en) * 1992-05-29 2000-08-15 Procter & Gamble Pharma SULFUR CONTAINING PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF ABNORMAL CALCIUM AND PHOSPHATE METABOLISM
CA2151240A1 (en) * 1992-12-23 1994-07-07 Donna T. Whiteford Biophosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (en) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen A method for handling endo-osteal materials
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Similar Documents

Publication Publication Date Title
RU96121563A (en) USE OF BISPHOSPHONATES FOR INHIBITION OF BONE RESORPTION ARISING FROM IMPLANTATION OF ORTHOPEDIC PROSTHESES
CA2188030A1 (en) Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis
US5403829A (en) Use of bisphosphonates in endo-osteal bone surgery
Boyne et al. A technique for osseous restoration of deficient edentulous maxillary ridges
US5733564A (en) Method of treating endo-osteal materials with a bisphosphonate solution
ATE289199T1 (en) FORMULATIONS CONTAINING THE ANHYDROUS MONONATRUM SALT OF ALENDRONATE AND THEIR USE FOR THE TREATMENT OF BONE DISEASES
WO1992016170A1 (en) Temporomandibular joint prosthesis
Iizuka et al. Chronic recurrent anterior luxation of the mandible: A review of 12 patients treated by the LeClerc procedure
KR100453779B1 (en) Use of ibandronate for promoting osseointegration of endoprostheses
KR970705400A (en) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE USING BONE ACTIVE PHOSPONATE AND PARTHROPHONE HORMONE
MX9604968A (en) Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis.
Madjar et al. Dynamic labial commissure widening device for the facial burn patient.